-- （からのコメント要請に対するInhibrxの回答を追記） ロイター通信は水曜日、関係者の話として、ドイツのメルク（MRK）と日本の小野薬品工業が、Inhibrx Biosciences（INBX）の実験的抗がん剤に関心を示していると報じた。この抗がん剤は80億ドル以上の価値があるとみられている。 関係者によると、Inhibrxは治療薬INBRX-106と、もう一つの実験的抗がん剤の共同スピンオフを検討しており、臨床試験が成功すれば、これら2つの抗がん剤の合計価値は90億ドルを超える可能性があるという。 Inhibrxはの取材に対しコメントを拒否し、メルクと小野薬品工業はコメント要請にすぐには応じなかった。 （マーケットチャッターのニュースは、世界中の市場専門家との会話に基づいています。この情報は信頼できる情報源に基づいていると考えられますが、噂や憶測が含まれる可能性があります。正確性は保証されません。）
Price: $112.88, Change: $+0.32, Percent Change: +0.28%
Easou Technology (HKG:2550) said it has subscribed to a $7.7 million wealth management product issued by Huatai International Financial Products, using idle proceeds from its earlier placings, according to a Friday Hong Kong bourse filing.Shares of the digital service firm were down over 1% in Monday's late-morning trade.The investment, guaranteed by Huatai International Financial, carries an annualized return of 1.07% to 5.83% over a term ending March 30, 2027.Easou said the move aims to enhance the utilization efficiency and returns on idle funds while maintaining liquidity.
SSY Group (HKG:2005) said it received Chinese regulatory approval to begin drug production and registration of its diltiazem hydrochloride in injection form, according to a Hong Kong bourse filing Monday.The drug is mainly used to treat a heart condition known as supraventricular tachycardia and the emergency treatment of abnormally high blood pressure during surgery.The firm's propranolol hydrochloride injection was also approved for production and registration by China's National Medical Products Administration.The product is mainly used to treat supraventricular tachyarrhythmias and ventricular arrhythmias.
Amplitude Energy (ASX:AEL) said Australian Retirement Trust raised its stake in the firm to 6.3% as of Friday from 5.1% as of April 2, according to a Monday Australian bourse filing.Australian Retirement Trust now holds nearly 19 million votes in the firm.